Ebivanta Therapeutics

On a mission to eliminate Epstein-Barr virus with a next gen mRNA vaccine

Epstein–Barr virus (EBV) infects more than 90% of the global population and is the leading cause of infectious mononucleosis (glandular fever). Despite more than 50 years of research, there is still no licensed vaccine to prevent EBV infection, representing one of the largest remaining unmet needs in infectious disease prevention. Lifelong EBV infection also significantly increases the risk of multiple cancers, including nasopharyngeal carcinoma, Hodgkin lymphoma, Burkitt lymphoma and gastric cancer, and is strongly associated with autoimmune diseases such as multiple sclerosis.

Ebivanta Therapeutics has developed a next-generation mRNA vaccine that combines multiple EBV antigens to generate both potent virus neutralising antibodies and broad T-cell immunity. Unlike previous vaccine candidates that primarily focus on antibody responses, Ebivanta’s  vaccine is designed to prevent viral entry while eliminating infected cells, providing comprehensive immune protection. Preclinical studies have demonstrated strong immunogenicity, with high neutralising antibody titres and robust multi-antigen T-cell responses. Built on a scalable mRNA platform, the vaccine has a clear pathway to clinical development and commercial manufacture.

Biointelect Venturer funding for this project supports optimisation of vaccine manufacture, completion of pivotal preclinical efficacy and safety studies, GMP process development, regulatory planning, and preparation for first-in-human clinical trials. This support will significantly de-risk the program, accelerate commercial readiness, and position Australia at the forefront of next-generation mRNA vaccines for EBV.

If successful, Ebivanta Therapeutics’ vision is to deliver the world’s first vaccine capable of preventing primary EBV infection, eliminating infectious mononucleosis and reducing the lifetime risk of EBV-associated cancers and autoimmune diseases. This has the potential to deliver substantial health, social and economic benefits worldwide.

  • BV Round 1 Project: mRNA Vaccine
  • State: QLD
  • Project Lead: Professor Rajiv Khanna
  • Biointelect Venturer Funding: $1,500,000

Eri Nishiuchi

Strategic Development and Business Effectiveness

Eri Nishiuchi holds a Bachelor of Business degree from the University of Technology Sydney. Her expertise lies in health systems analysis and client relationship management within the healthcare and life sciences sectors. She also has experience working with patient organisations.

Throughout her career, Eri has provided competitive landscape research support to pharmaceutical and biotech clients across the Asia Pacific region, achieving one of the top client retention rates in the region. Her multilingual abilities have been instrumental in fostering strong relationships with diverse stakeholders.

Eri joined Biointelect in 2024 in a strategic development and business effectiveness role, where her focus will be on conducting market analysis and improving business processes.